AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Oral triple-drug therapy is an effective and underutilized strategy in type 2 diabetes, Dr. Diana Dills said at a meeting of the Colorado chapter of the American College of Physicians-American Society of Internal Medicine.
Here's what triple-drug therapy with metformin, a sulfonylurea, and a glitazone accomplishes, as demonstrated in a 200-patient trial in which patients on metformin and a sulfonylurea were randomized to troglitazone or placebo. After 24 weeks, the mean fasting blood glucose in the triple-drug therapy group was 43 mg/dL lower, and hemoglobin [A.sub.1c] (Hb[A.sub.1c]) was 1.3% lower than in patients on two drugs plus placebo, observed Dr. Dills, a diabetologist at the University of Colorado, Denver.
Troglitazone (Rezulin) is now off the market due to safety issues, and there are no data on triple-drug therapy using the glitazones that are now available: rosiglitazone and pioglitazone. The ...
Source: HighBeam Research, Oral Triple-Drug Therapy.